These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9588400)

  • 1. New antiplatelet agents for acute coronary syndromes.
    Ferguson JJ; Lau TK
    Am Heart J; 1998 May; 135(5 Pt 2 Su):S194-200. PubMed ID: 9588400
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
    Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract]   [Full Text] [Related]  

  • 5. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Nursing; 1999 Dec; 29(12):34-9; quiz 40. PubMed ID: 10797693
    [No Abstract]   [Full Text] [Related]  

  • 6. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Westerhout CM; Boersma E
    Expert Opin Drug Saf; 2003 Jan; 2(1):49-58. PubMed ID: 12904124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
    Jennings LK
    Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa inhibitors.
    Stevens M
    Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 19. [GPIIb-IIIa inhibitors].
    Nurden P
    Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
    Iakovou I; Dangas G; Mehran R; Lansky AJ; Kobayashi Y; Adamian M; Polena S; Collins MB; Roubin GS; Stone GW; Leon MB; Moses JW
    Am J Cardiol; 2002 Apr; 89(8):976-9. PubMed ID: 11950440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.